The 2026 European Lung Cancer Congress (ELCC 2026) will be held in Copenhagen, Denmark, from March 25 to 28 (local time). ELCC is one of the most influential international academic conferences in the global lung cancer field.
Long-term follow-up data on overall survival (OS) from the Phase III clinical study of Lieritinib Tablets (brand name: Aoyixin?)—a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)—for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations will be presented for the first time at the 2026 ELCC.
Lieritinib is an oral third-generation EGFR-TKI indicated for the treatment of locally advanced or metastatic NSCLC with EGFR mutation-positive status. The Phase III clinical study was a multicenter, randomized, double-blind, active-controlled trial conducted across 56 clinical centers in China. Patients with EGFR-sensitizing mutations (19del or L858R) receiving first-line treatment were randomized 1:1 to receive either Lieritinib or Gefitinib, with progression-free survival (PFS) as the primary endpoint. Led by Professor Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences, the study results have been published in The Lancet Respiratory Medicine (Impact Factor: 32.8). Findings demonstrated that Lieritinib exhibited significant efficacy and safety in patients with EGFR-sensitizing mutation-positive advanced NSCLC receiving first-line treatment, with particularly notable efficacy in patients with brain metastases.
In previously published data, the maturity of OS data from the Lieritinib Phase III study was relatively low. As follow-up duration continues to extend, OS—recognized as the “gold standard” endpoint in oncology—holds critical significance for evaluating the long-term survival benefits of therapeutic interventions. The updated OS data to be presented at the 2026 ELCC Congress, based on extended follow-up, is expected to clarify the long-term survival benefits of Lieritinib in first-line treatment of patients with EGFR-mutated NSCLC, validate its value in translating delayed disease progression into survival advantage, further consolidate its therapeutic advantages in special populations such as those with brain metastases, and provide higher-level evidence-based medical evidence to inform clinical practice.